BRANFORD, Conn., April 29 — Core Informatics announces

that it has delivered an installation of their Enterprise Core LIMS product

to BioRelix Pharmaceuticals of New Haven, CT. BioRelix, which started

laboratory operations in late 2007, recognized the need to establish a

strong data management infrastructure from the beginning. After conducting

an extensive survey of the LIMS marketplace, BioRelix choose the Core LIMS.

“After our evaluation it became very clear that the Core LIMS was the

best product for our needs,” said Ken Blount, Director of Biology for

BioRelix. “Their product provides us with an opportunity to manage data for

our entire drug discovery process in a single enterprise wide system.”

One of the benefits of the Core LIMS is its component-based

architecture, which allows customers to choose only the components of their

system that are required to meet their current needs. “As BioRelix grows

and their needs change to require, for example, in-life studies, they can

purchase additional components for the Core LIMS to enable that growth,”

said James Gregory, Chief Software Architect of Core Informatics.

About Core Informatics

Core Informatics is a software company focused on delivering state of

the art, fully customized Laboratory Information Management Systems (LIMS)

to customers in a variety of industries. Their signature product, The Core

LIMS, is a web-based LIMS that features a component-based architecture,

which provides its clients the freedom to pick and choose only the

functionality relevant to their specific research. The company provides its

products via three modes of delivery: LIMS appliances, hosted LIMS and

enterprise LIMS.

For more information about Core Informatics, please visit

http://www.corelims.com.

About BioRelix Pharmaceuticals

BioRelix Pharmaceuticals, Inc. is a drug discovery and development

company focused on identifying new anti-infective drug treatments. BioRelix

is building a portfolio of anti-infective products based on novel patented

RNA targets, termed RiboSwitches, which were identified in the laboratory

of BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator

and Henry Ford II Professor at Yale University. BioRelix investors include

CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis

Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.

For more information about BioRelix Pharmaceuticals, please visit

http://www.biorelix.com.